SCHEMBL6500196

SCHEMBL6500196

Nc1cc(C(Br)C(=O)c2cccc(Cl)c2)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.43
SLC6A2 P23975 5/20 0.40
SLC6A3 Q01959 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CHRNA1 P02708 2/20 0.40
CHRNG P07510 2/20 0.40
CHRNB1 P11230 2/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
SLC6A4 P31645 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA4 P43681 2/20 0.40
CHRND Q07001 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
ITGA5 P08648 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL3888929 0.99 PARP1 (0.42) PARP1SLC6A2SLC6A3SMN1; SMN2CHRNA1
SCHEMBL6505974 0.85 PARP1 (0.44) PARP1SLC6A2SLC6A3SMN1; SMN2CHRNA1
SCHEMBL6499506 0.85 GABRP (0.41) SMN1; SMN2NPC1PKMRAB9AKCNH2
SCHEMBL6505647 0.84 PARP1 (0.43) PARP1SLC6A2SLC6A3CHRNA1CHRNG
Bromide SCHEMBL3892578 0.84 PARP1 (0.43) PARP1SLC6A2SLC6A3SMN1; SMN2CHRNA1
Bromide SCHEMBL3890064 0.84 GABRP (0.41) SMN1; SMN2NPC1PKMRAB9AKCNH2
Bromide SCHEMBL3891895 0.83 GABRP (0.46) CYP2C19TDP1ALDH1A1GABRPGABRD
Bromide SCHEMBL3889498 0.83 PARP1 (0.42) PARP1SLC6A2SLC6A3CHRNA1CHRNG
Bromide SCHEMBL3894827 0.83 SLC6A2 (0.39) PARP1SLC6A2SLC6A3SMN1; SMN2CHRNA1
Bromide SCHEMBL3886815 0.83 CES2 (0.46) PARP1SLC6A2SLC6A3CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
EP-1364949-A1 JNK INHIBITOR Takeda Chemical Industries, Ltd. (JP) 2003-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 PARP1 3236/4885SLC6A2 4327/4885SLC6A3 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.